Navigation Links
Daclizumab shows potential for new immunoregulatory approach to treating MS
Date:2/16/2010

active lesions, supports further study of daclizumab."

Multiple sclerosis, one of the most common neurological disorders, affects more than 400,000 people in the United States each year. Despite significant advances in MS therapy, many patients continue to experience disease activity. There is a need for additional MS therapies that offer new approaches to treating the disease.

Daclizumab is a humanized monoclonal antibody that binds to CD25, a high affinity receptor that is expressed at low levels on resting T cells, which are a type of immune cell, and at high levels on T cells that can become activated in response to autoimmune conditions such as MS.

"Daclizumab is believed to work by selectively targeting immune cells that play a key role in MS without depleting healthy immune cells and has the potential to provide a new approach to treating this chronic and debilitating disease," said Gilmore O'Neill, senior director, Experimental Neurology at Biogen Idec. "Daclizumab was well tolerated in the CHOICE trial and significantly reduced MS activity in patients who were not responding to interferon beta."

"We believe the results from the CHOICE study, combined with clinical data from smaller trials of daclizumab in MS, provide a basis for advancing daclizumab into registrational studies as a novel therapeutic for the treatment of patients with relapsing MS," said Mark Rolfe, Ph.D., senior vice president and chief scientific officer of Facet Biotech. "Despite advances in MS treatment, there remains a significant unmet medical need for new therapies such as daclizumab and we look forward to seeing data from our registrational studies."

Results from this Phase 2 study provided evidence for Biogen Idec and Facet Biotech to continue the development of daclizumab in two registrational trials in MS. The Phase 2b SELECT trial is evaluating the efficacy and safety of monthly subcutaneous daclizumab as a monotherapy versus place
'/>"/>

Contact: Kate Weiss
617-914-6524
GCI Health
Source:Eurekalert

Page: 1 2 3 4

Related biology technology :

1. Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy
2. Mescal worm test shows DNA leaks into preservative liquids
3. Boost for Prostate Cancer Screening - Report Shows Mortality Reduction as High as 31%
4. Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy
5. UCBs Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis
6. Tiny test tube experiment shows reaction of melting materials at the nano scale
7. New Survey Shows Devastating Impact of Rheumatoid Arthritis Pain on Intimate Relations
8. Topical erectile dysfunction therapy shows promise
9. Study on keeping nuclear bombs from US ports shows misplaced fear over cargo scanning cost
10. Medicagos H1N1 pandemic vaccine candidate shows positive response in 100% of vaccinated animals after a single dose
11. Video shows nanotube spins as it grows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , Aug. 27, 2015 /PRNewswire/ - Portage ... Exchange: PBT.U), and Biohaven Pharmaceutical Holding Company Limited ... a Phase I study of BHV-0223, a glutamate ... (IND) regarding BHV-0223 and recently obtained clearance from ... proceed with human testing. Portage holds 54% equity ...
(Date:8/27/2015)... Aug. 27, 2015 HUYA Bioscience International (HUYA) today ... the Japan Society of HTLV-1, held this week at ... purpose of the Society is to promote research on ... of medical technology and research related to these fields ... "HUYA is proud to support this prestigious conference," ...
(Date:8/27/2015)... 27, 2015 In response to recent ... and The US Postal Service to no longer ... ,select agents, by the CDC, Marken reaffirmed today ... sensitive shipments. Marken uses its flexible ... and certified personnel to ensure the safe and ...
(Date:8/26/2015)... , Aug. 26, 2015  Roka Bioscience, Inc. (NASDAQ: ... providing advanced testing solutions for the detection of foodborne ... present at the Sidoti & Company Emerging Growth Conference ... be held at the New York Marriott Marquis. ... be available through the investor relations section of Roka ...
Breaking Biology Technology:Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4Marken Ensures Safe Transportation Of Select Agents And Toxins 2
... adds advanced cholesterol testing capabilities, BIRMINGHAM, ... company, today announced that its VAP(R) Cholesterol ... released health,assessment, BiophysicalCheck., The announcement means ... ability to,identify far more areas of risk ...
... (Nasdaq: BCRX ) today announced that its ... Thursday, August 7, 2008. Following,the release, BioCryst will ... a.m.,Eastern Time to discuss the financial results and ... will be led by Jon P. Stonehouse, BioCryst,s,Chief ...
... 31 NeoStem, Inc. (Amex: NBS ),has announced ... cell,collection centers. Through a development agreement with Stem Collect ... Monica based medical,practice., The Los Angeles area is ... a large concentration of physician practices,and hospitals offering a ...
Cached Biology Technology:VAP(R) Cholesterol Test Bolsters Biophysical(R) Health Assessment 2VAP(R) Cholesterol Test Bolsters Biophysical(R) Health Assessment 3BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008 2BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008 3NeoStem Expands Adult Stem Cell Collection Network, Gains Footprint in Key Los Angeles Market and Initiates Waitlist 2NeoStem Expands Adult Stem Cell Collection Network, Gains Footprint in Key Los Angeles Market and Initiates Waitlist 3
(Date:8/20/2015)... 20, 2015 The wearable technology market ... active and healthy. However, wearable technology has the ... to help improve diagnostic capabilities and therapeutic outcomes. ... Wearable Technologies Conference 2015 , where ... wearables in healthcare.    "Over the ...
(Date:8/18/2015)... Aug. 18, 2015  Navitas today announced ... to the Submission Content Management webinar scheduled ... non-profit forum. Dedicated to the Implementation of Regulatory ... platform for industry, vendors, health authorities, consultants ... work towards a standard method of implementing ...
(Date:8/12/2015)... August 12, 2015 As the ... payment innovation and advanced biometrics technology is accelerating beyond ... consumers rely on using their credit cards, the digital ... future for payment services led by companies in the ... :  Google, Inc. (NASDAQ: GOOG ), Apple Inc. ...
Breaking Biology News(10 mins):Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6
... Bergen in Norway have found new support for their ... in non-psychotic individuals, leading to long-term psychosis. In an ... Psychiatry , researchers found a different brain activity pattern ... schizophrenic patients without prior cannabis use. The ...
... (Santa Barbara, Calif.) UC Santa Barbara has reported an ... findings uncover dynamic changes in brain coordination patterns between left ... decades, and scientists have long ago shown that language processing ... When words appear only in the left visual field ...
... agricultural biotech projects, according to Canadian researchers who today ... built or undermined trust in eight African case studies. ... UK-based journal Agriculture and Food Security , the ... University Health Network and the University of Toronto, concluded ...
Cached Biology News:Cannabis use mimics cognitive weakness that can lead to schizophrenia 2UCSB scientists report 'new beginning' in split-brain research, using new analytical tools 2UCSB scientists report 'new beginning' in split-brain research, using new analytical tools 3UCSB scientists report 'new beginning' in split-brain research, using new analytical tools 4Study details essential role of trust in agricultural biotech partnerships 2Study details essential role of trust in agricultural biotech partnerships 3Study details essential role of trust in agricultural biotech partnerships 4Study details essential role of trust in agricultural biotech partnerships 5Study details essential role of trust in agricultural biotech partnerships 6
... Plus is formulated for covering tissue sections and ... soluble OR alcohol insoluble end products. ... as Fast Red or AEC that require an ... such as DAB. No heating is required prior ...
... (phospho Y1007) ( Abpromise for ... Antigen: Synthesized phosphopeptide derived from ... of tyrosine 1007 (K-E-Y P -Y-K). ... 3717 Swiss ...
Rabbit polyclonal to JNK1 (phospho T183 + Y185) ( Abpromise for all tested applications). entrezGeneID: 5599 SwissProtID: P45983...
... Rabbit polyclonal to JMJD2D ( Abpromise ... Antigen: Synthetic peptide conjugated to ... 500 of Human JMJD2D.(Note: the amino acid ... .) Entrez Gene ID: ...
Biology Products: